Background: The success of allergic rhinitis (AR) therapy has not yet been achieved because 76% of patients with AR still experience symptoms of nasal obstruction despite receiving oral AH. The symptom of a blocked nose at night is the most disturbing in 80% of patients with AR. Complaints of nasal congestion that persist after administration of AH are associated with swelling of the nasal mucosa caused by cysteine leukotrienes (CystLTs). The severity of AR symptoms can be assessed by the daytime nasal symptoms score (DNSS) and nighttime symptoms score (NSS). Objective: To know the difference between DNSS and NSS between the combination of montelukast and loratadine and single loratadine in patients with AR. Methods: Meta-analytical study, with Science Direct database, PubMed central and publisher website, Cochrane library, ResearchGate, and SAGE journals, year of publication limited to the last twenty-five years, randomized controlled trial, comparison single loratadine. DNSS and NSS differences assessment is based on the mean difference (MD). Test for heterogeneity using RevMan 5.4. Results: The search for articles found 777, with 3 articles meeting the eligibility criteria, 3 assessment articles based on DNSS and two articles based on NSS. The use of the combination of montelukast and loratadine did not show a significant reduction in DNSS (MD -0.11; 95% CI -0.25 to 0.03; p=0.13; I2=73%) and show a significant reduction in NSS (MD -0.05; 95% CI -0.10 to -0.00; p=0.004; I2=37%). Conclusion: There was no difference in DNSS between montelukast and loratadine combined with single loratadine in AR patients. There was no difference in NSS between montelukast and montelukast loratadine combined with single loratadine in AR.

Allergic rhinitis

montelukast

loratadine